Jones Financial Companies Lllp Acquires 4,312 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Jones Financial Companies Lllp raised its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 303.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 5,733 shares of the biotechnology company’s stock after buying an additional 4,312 shares during the period. Jones Financial Companies Lllp’s holdings in ADMA Biologics were worth $98,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Healthcare of Ontario Pension Plan Trust Fund raised its stake in ADMA Biologics by 13.9% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company’s stock valued at $13,171,000 after buying an additional 80,400 shares during the last quarter. Lord Abbett & CO. LLC purchased a new stake in ADMA Biologics during the 3rd quarter valued at $61,858,000. EWG Elevate Inc. purchased a new stake in ADMA Biologics during the 4th quarter valued at $480,000. Citigroup Inc. raised its stake in ADMA Biologics by 251.7% during the 3rd quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company’s stock valued at $7,741,000 after buying an additional 277,138 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in ADMA Biologics by 1,144.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock valued at $51,016,000 after buying an additional 2,613,482 shares during the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Trading Up 2.9 %

NASDAQ:ADMA opened at $18.43 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The firm has a market capitalization of $4.36 billion, a price-to-earnings ratio of 65.82 and a beta of 0.60. ADMA Biologics, Inc. has a one year low of $5.88 and a one year high of $23.64. The business has a fifty day moving average price of $16.67 and a 200-day moving average price of $17.96.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 target price on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.